3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
6
Neoplasms
4
Multiple Myeloma
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Sarcoma
2
Radiation Injuries
2
Osteosarcoma
2
Melanoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Cognitive Dysfunction
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Thoracic Neoplasms
1
Testicular Neoplasms
1
Substance-Related Disorders
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Interventions
Surveys and Questionnaires
9
Cystectomy
6
Blood Specimen Collection
5
Neoadjuvant Therapy
4
Cystoscopy
4
Drug Therapy
3
avelumab
2
Urination
2
Urinary Diversion
2
Surgical Procedures, Operative
2
Radiotherapy
2
Pioglitazone
2
Microarray Analysis
2
Methods
2
Magnetic Resonance Spectroscopy
2
Interviews as Topic
2
Immunohistochemistry
2
Defecation
2
Biopsy
2
5-aminolevulinic acid hexyl ester
2
trastuzumab deruxtecan
1
sargramostim
1
pembrolizumab
1
erdafitinib
1
enfortumab vedotin
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Watchful Waiting
1
Urinary Sediment Analysis
1
Therapeutics
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Urinary Bladder Neoplasms
×
Patient Reported Outcome Measures
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled